[Psoriasis. Treatment].
OBJECTIVE
The aim of treatment in psoriasis is to reduce the degree of extension to a point compatible with the patients social, occupational and personal lifestyle. The patient should be informed that there is no curative treatment. A good patient-doctor relationship is required for the patient to understand that the proposed treatment can provide symptomatic relief but must take into account an optimal balance between treatment benefit and risk. Therapeutic abstention must be recognized as a possibility. In all cases, efforts must be made to recognize and eliminate if possible any favoring factors. A TWO-PHASE TREATMENT: Initially, the aim of the treatment is to induce an involution of the active lesions. A second phase is aimed at avoiding subsequent fiare-ups. Local treatments: Local care should always be preferred in patients with limited lesions. Keratolytic agents, dermocorticoids and vitamin D3 derivatives can be used. Topical retinoids, particularly tazarotene are in the development stage.
Systemic treatments should be reserved for extensive psoriasis and for failure after well-conducted local care. Photoherapy, particularly PUVA-therapy and more recently narrow-spectrum UVB-therapy play an important role. Systemic retinoids can be used alone or in combination with PUVA-therapy. The risks of methrotrexate and cyclosporin impose their use exclusively in specialized centers. Several other treatments are still in the experimental stage, particularly promising highly selective immunotherapy.
Chiaverini
C
C
Service de Dermatologie, Hôpital de l'Archet 2, Nice.
Desruelles
F
F
Lacour
J P
JP
Ortonne
J P
JP
D000287:Administration, Topical; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002762:Cholecalciferol / Q000008:administration & dosage; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D011701:PUVA Therapy; D011565:Psoriasis / Q000628:therapy*; D012176:Retinoids / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007641:Keratolytic Agents; D012176:Retinoids; D002762:Cholecalciferol
Psoriasis. Traitement.